Key Takeaways
Transcranial magnetic stimulation (TMS)
A noninvasive brain stimulation treatment in which an electromagnet held against the head is switched on and off very rapidly, inducing weak electrical currents that stimulate neurons and neural circuits beneath the coil[1]. When pulses are delivered in repeated trains, the treatment is called repetitive TMS (rTMS).
Related Terms
Source: National Institute of Mental Health
What Is TMS Therapy?
TMS therapy is transcranial magnetic stimulation: a noninvasive treatment that sends magnetic pulses through the scalp and skull to change activity in targeted brain regions, without surgery or anesthesia[1]. The FDA first cleared it in 2008 for major depression in people who had not responded to antidepressants[5], and it remains most closely tied to treatment-resistant depression.
The label now covers more than depression. U.S. clearances include obsessive-compulsive disorder, depression with anxious distress, migraine and short-term smoking cessation[2].
This explainer covers the technology itself: how it works, which devices and protocols exist, what each FDA clearance rests on, and how it compares with other brain stimulation. Depression-specific response rates, durability and insurance rules are covered in detail in TMS treatment for depression.
How Does TMS Work?
TMS runs on electromagnetic induction. A coil carries a brief, strong current that produces a magnetic field roughly as strong as an MRI scanner's; switching it on and off very rapidly induces weak electrical currents in the brain tissue under the coil[1].
Those induced currents depolarize neurons in the cortical tissue beneath the coil[6]. Where the coil sits depends on the condition: the left prefrontal cortex for depression, and the dorsomedial prefrontal cortex or anterior cingulate cortex for OCD[1].
The American Psychiatric Association describes the aim as stimulating underactive areas or calming overactive ones, with repeated sessions thought to strengthen neuroplasticity, the brain's capacity to change its connections[2]. The exact mechanism is still being studied, and that framing is a working model rather than a settled account.
Where TMS came from
The method traces to a 1985 report in The Lancet by Barker, Jalinous and Freeston at the University of Sheffield, which described non-invasive magnetic stimulation of the human motor cortex[7]. Clinical use for psychiatric conditions followed, ending in the first FDA clearance for depression in 2008 with the Neuronetics NeuroStar system[5].
What Conditions Is TMS FDA-Cleared to Treat?
TMS devices reach the market through FDA device pathways, so each clearance applies to a specific device and protocol rather than to TMS in general. NIMH lists treatment-resistant depression, OCD, migraine, depression with anxiety and smoking dependence as cleared uses[1].
The OCD, migraine and smoking uses were each tested against sham stimulation, which mimics the sound and scalp sensation of TMS without stimulating the brain[6]. For OCD, the FDA reviewed a 100-patient trial in which 38% of those on the Brainsway deep TMS device improved by more than 30% on the Y-BOCS symptom scale, versus 11% on sham[3].
For migraine with aura, a portable single-pulse device used during the aura left 39% of patients pain-free at 2 hours, versus 22% with sham, in an 18-center U.S. trial[8]. For smoking, the FDA cleared the Brainsway Deep TMS System as a smoking cessation device in August 2020[9]. In the pivotal trial of 262 smokers, each session followed a cue-induced craving exercise, and 19.4% of the active group quit continuously through week 18, versus 8.7% with sham[6].
Age limits apply. In March 2024 the FDA cleared rTMS as an add-on treatment for depression in adolescents 15 and older, and it is not approved for anyone younger[1].
FDA Milestones for TMS Devices
| Year | Cleared use | Device or approach | Key trial result |
|---|---|---|---|
| 2008 | Major depression after antidepressant non-response | NeuroStar rTMS | First U.S. TMS clearance |
| 2013 | Pain from certain migraine headaches | TMS for migraine | Single-pulse trial, pain-free at 2 h: 39% vs 22% sham |
| 2018 | Obsessive-compulsive disorder | Brainsway deep TMS | Response: 38% vs 11% sham |
| 2020 | Short-term smoking cessation | Brainsway deep TMS | Quit through week 18: 19.4% vs 8.7% sham |
| 2024 | Adjunctive depression treatment, ages 15+ | rTMS | Extends depression use to older teens |
Selected U.S. FDA clearances for transcranial magnetic stimulation, with a key sham-controlled result for each use; depression with anxious distress and an accelerated depression protocol have also been cleared[1].
1Dates: 2008 from Cohen et al.[5]; 2013 and 2018 from the FDA[3]; 2020 from the FDA 510(k) database[9]; 2024 from NIMH[1].
2Trial results: migraine[8]; OCD[3]; smoking, intent-to-treat continuous quit rate[6].
Sources
- •FDA, 2018 and 2020
- •NIMH, 2024
- •Cohen et al., Brain Stimulation, 2022
- •Lipton et al., Lancet Neurology, 2010
- •Zangen et al., World Psychiatry, 2021
Patients with depression who responded to TMS, per the American Psychiatric Association
The APA reports that about one in two patients treated with TMS for depression showed a significant improvement in symptoms and about one in three reached remission. TMS is typically added to medication for people who have not fully responded to antidepressants alone.
"one in two patients who underwent TMS demonstrated a response"
Types of TMS: rTMS, Deep TMS, Theta Burst and Accelerated Protocols
Since 2008, refinements have produced new pulse patterns such as intermittent theta burst stimulation (iTBS) and 18 to 20 Hz trains, neuronavigation systems that guide coil placement, and new coil designs[5]. Clinics now offer several distinct versions.
- Repetitive TMS (rTMS): the original form, delivering trains of pulses to one target. A standard 10 Hz session for depression lasts 37.5 minutes[4].
- Deep TMS: uses helmet-mounted H-coils[6], sometimes two coils together, to reach larger and deeper structures[1]. The OCD and smoking clearances are both for deep TMS devices[3][9].
- Theta burst stimulation (iTBS): packs pulses into rapid bursts, so a session takes 3 minutes[4].
- Accelerated TMS: compresses a course into days by giving several sessions per day[2].
- Single-pulse TMS: a portable device for migraine that delivers individual pulses during an aura[8].
In a head-to-head test, shorter sessions did not cost effectiveness. In the THREE-D trial of 414 adults with treatment-resistant depression, depression scores fell from 23.6 to 13.4 with iTBS and from 23.5 to 13.4 with 10 Hz rTMS, meeting the non-inferiority test[4].
One accelerated protocol, Stanford Neuromodulation Therapy (SNT, formerly called SAINT), uses 10 iTBS sessions a day for 5 consecutive days, with the target chosen from each patient's functional connectivity scan[10]. In its 29-patient sham-controlled trial, 78.6% of the active group reached remission during 4 weeks of follow-up, versus 13.3% on sham[10]. The trial was small, and its authors called for more research on durability and on comparisons with other treatments[10].
What Happens During a TMS Session?
A psychiatrist first screens for factors that rule TMS out, then sets the treatment parameters[2]. At the first session, the operator measures the patient's individual motor threshold, which sets the treatment site and strength while limiting side effects[2].
During treatment the patient sits awake while the coil rests against the head, and the pulses feel like a knocking or tapping on the scalp[1]. Earplugs are worn during treatment because they prevent hearing loss, one of the uncommon risks[2].
A standard course is five sessions a week for four to six weeks[2]. The APA puts each session at 3 to 30 minutes[2], and NIMH at 3 to 40 minutes[1]. No anesthesia is used, and patients can drive themselves to and from appointments[2].
TMS Side Effects, Safety and Who Should Not Have It
NIMH describes rTMS as safe and well tolerated, with side effects that include discomfort where the coil sits, tingling or contraction of scalp, jaw or face muscles, mild headache, brief lightheadedness and dizziness[1]. The APA reports no known cognitive side effects[2].
Headache is the most frequently reported complaint in trials, and it also occurs with sham treatment. In the OCD trial, 37.5% of the active group and 35.3% of the sham group reported headache[3]. In THREE-D, headache occurred in 64% of the 10 Hz group and 65% of the iTBS group[4].
Uncommon risks include severe headache, fainting, hearing loss without ear protection and seizure, which the APA puts at about 1 in 10,000[2]. Long-term side effects have not been established[1].
Who is not a candidate
The strong magnetic field rules out people with metal implants in the head, aneurysm clips or coils, cochlear implants or cardiac defibrillators, and people with a history of epilepsy are also excluded[2].
How Is TMS Different From ECT and Other Brain Stimulation?
TMS is one of several brain stimulation therapies, and the differences are mostly about how energy reaches the brain. Electroconvulsive therapy (ECT) applies electricity directly to the head under anesthesia and stimulates the brain broadly; TMS uses magnetic pulses aimed at one site, needs no anesthesia and can be given in an office[1].
The tradeoff is strength of effect. NIMH states that rTMS does not match the therapeutic effects of ECT[1].
Vagus nerve stimulation (VNS) and deep brain stimulation (DBS) require surgery. The FDA approved surgical VNS for depression in 2005 for adults whose depression lasted 2 or more years and did not ease after at least four other treatments, and DBS requires implanting electrodes in the brain[1].
Who Gets TMS, and What Is Still Experimental?
In practice, TMS is mostly used after medication has not worked. The original 2008 clearance covered people who had not responded to at least one antidepressant in the current episode, and it is now used for moderate to severe depression when medications have been ineffective or intolerable[1].
TMS is typically given alongside medication rather than in place of it[2]. Background on the condition itself is on the major depressive disorder page.
Insurers often set stricter rules than the FDA label. Many carriers cover standard TMS only after three to four prior antidepressant trials have failed[2].
Bipolar depression is not an FDA-cleared use; the agency gave rTMS a breakthrough device designation for it in 2020, a status for devices with preliminary evidence of effectiveness that allows quicker review, not a clearance[1][2]. Medication options for depression are summarized in anti-depression meds.
Frequently Asked Questions
Sources & References
- National Institute of Mental Health. Brain Stimulation Therapies. National Institutes of Health. Published 2024. Accessed October 2026. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies [Link]
- American Psychiatric Association. What is TMS? American Psychiatric Association. Published 2026. Accessed October 2026. https://www.psychiatry.org/patients-families/what-is-tms [Link]
- U.S. Food and Drug Administration. FDA permits marketing of transcranial magnetic stimulation for treatment of obsessive compulsive disorder. U.S. Food and Drug Administration. Published 2018. Accessed October 2026. https://www.fda.gov/news-events/press-announcements/fda-permits-marketing-transcranial-magnetic-stimulation-treatment-obsessive-compulsive-disorder [Link]
- Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial. The Lancet. Published 2018. Accessed October 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30295-2/abstract [Link]
- Cohen SL, Bikson M, Badran BW, George MS. A visual and narrative timeline of US FDA milestones for transcranial magnetic stimulation (TMS) devices. Brain Stimulation. Published 2022. Accessed October 2026. https://www.brainstimjrnl.com/article/S1935-861X(21)00825-1/fulltext [Link]
- Zangen A, Moshe H, Martinez D, et al. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. World Psychiatry. Published 2021. Accessed October 2026. https://onlinelibrary.wiley.com/doi/10.1002/wps.20905 [Link]
- Barker AT, Jalinous R, Freeston IL. Non-invasive magnetic stimulation of human motor cortex. The Lancet. Published 1985. Accessed October 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(85)92413-4/fulltext [Link]
- Lipton RB, Dodick DW, Silberstein SD, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomised, double-blind, parallel-group, sham-controlled trial. The Lancet Neurology. Published 2010. Accessed October 2026. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(10)70054-5/abstract [Link]
- U.S. Food and Drug Administration. 510(k) Premarket Notification K200957: Brainsway Deep TMS System (transcranial magnetic stimulation system for smoking cessation). U.S. Food and Drug Administration. Published 2020. Accessed October 2026. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K200957 [Link]
- Cole EJ, Phillips AL, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. American Journal of Psychiatry. Published 2022. Accessed October 2026. https://psychiatryonline.org/doi/10.1176/appi.ajp.2021.20101429 [Link]